![](/wp-content/uploads/rapidlogo.png)
April 1, 2024
BURLINGTON, Ontario – April , 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...
![](/wp-content/uploads/rapidlogo.png)
March 25, 2024
BURLINGTON, Ontario – March 25, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $6,000,000 of gross proceeds, consisting of up to 35,294,117 common shares...
![](/wp-content/uploads/rapidlogo.png)
February 29, 2024
BURLINGTON, Ontario – February 28, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that effective February 28, 2024 (the “Effective Date”), the Company has cancelled an aggregate of 5,350,000 stock options (“Options”) to purchase common shares of the Company...
![](/wp-content/uploads/rapidlogo.png)
February 28, 2024
BURLINGTON, Ontario – February 23, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $200,000 in a second tranche of its previously announced equity private placement financing (the “Financing”), bringing the total amount raised to...
![](/wp-content/uploads/rapidlogo.png)
February 20, 2024
BURLINGTON, Ontario – February 16, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $1,100,000 in a first tranche of its previously announced equity private placement financing (the “Financing”) which contemplated up to $7,000,000 of...
![](/wp-content/uploads/rapidlogo.png)
February 8, 2024
Burlington, Ontario – February 7, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol MKT:DOSE announces the appointment of Angela O’Leary to the Board of Directors. Mark Upsdell, CEO of RDT said ““We are...
![](/wp-content/uploads/rapidlogo.png)
January 20, 2024
BURLINGTON, Ontario – January 19, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $7,000,000 of gross proceeds, consisting of up to 41,176,470 units (the...
![](/wp-content/uploads/rapidlogo.png)
December 22, 2023
BURLINGTON, Ontario – December 22, 2023 Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed on $855,000 in a fourth tranche of its previously announced private placement financing (the “Financing”) bringing the total amount invested to...
![](/wp-content/uploads/rapidlogo.png)
December 6, 2023
BURLINGTON, Ontario – December 6, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated November 14, 2023 announcing a third tranche closing of $500,000, thereby bringing the total amount invested to approximately $2,300,000,...
![](/wp-content/uploads/rapidlogo.png)
November 22, 2023
BURLINGTON, Ontario – November 22, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has retained Profinnotiv AG (the “Consultant”) to provide the Company with investor and public relations services in the European market, including brand...